Literature DB >> 29203992

Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer.

Yuji Miyamoto1,2, Wu Zhang1, Heinz-Josef Lenz1.   

Abstract

Over the last 20 years, median survival for patients with metastatic colorectal cancer (CRC) has remarkably improved from about 12 to over 30 months, mainly because of the development of new agents and patient selection using predictive biomarkers. However, the identification of the most effective treatment for an individual patient is still a challenge. Molecular profiling of CRC has made great progress, but it is limited by tumor heterogeneity and absence of driver mutation. However, RAS, BRAF, and microsatellite instability are validated biomarker recommended by NCCN and ESMO. In this review, we discuss recent advances and future developments.

Entities:  

Keywords:  Biomarker; Chemotherapy; Colorectal cancer; Molecular pathway; Personalized therapy; Targeted therapy

Year:  2016        PMID： 29203992      PMCID： PMC5705494          DOI： 10.1007/s13193-016-0543-z

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN： 0975-7651


  99 in total

1.  Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.

Authors:  Clara Montagut; Alba Dalmases; Beatriz Bellosillo; Marta Crespo; Silvia Pairet; Mar Iglesias; Marta Salido; Manuel Gallen; Scot Marsters; Siao Ping Tsai; André Minoche; Somasekar Seshagiri; Seshagiri Somasekar; Sergi Serrano; Heinz Himmelbauer; Joaquim Bellmunt; Ana Rovira; Jeff Settleman; Francesc Bosch; Joan Albanell
Journal:  Nat Med       Date:  2012-01-22       Impact factor: 53.440

2.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

Authors:  Ryan B Corcoran; Hiromichi Ebi; Alexa B Turke; Erin M Coffee; Michiya Nishino; Alexandria P Cogdill; Ronald D Brown; Patricia Della Pelle; Dora Dias-Santagata; Kenneth E Hung; Keith T Flaherty; Adriano Piris; Jennifer A Wargo; Jeffrey Settleman; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Cancer Discov       Date:  2012-01-16       Impact factor: 39.397

3.  Colon cancer mutation: prognosis/prediction--response.

Authors:  Patrick G Gavin; Soonmyung Paik; Greg Yothers; Kay L Pogue-Geile
Journal:  Clin Cancer Res       Date:  2013-02-08       Impact factor: 12.531

Review 4.  Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.

Authors:  M J Sorich; M D Wiese; A Rowland; G Kichenadasse; R A McKinnon; C S Karapetis
Journal:  Ann Oncol       Date:  2014-08-12       Impact factor: 32.976

5.  Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.

Authors:  Eric Van Cutsem; Heinz-Josef Lenz; Claus-Henning Köhne; Volker Heinemann; Sabine Tejpar; Ivan Melezínek; Frank Beier; Christopher Stroh; Philippe Rougier; J Han van Krieken; Fortunato Ciardiello
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

6.  FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.

Authors:  Chiara Cremolini; Fotios Loupakis; Carlotta Antoniotti; Cristiana Lupi; Elisa Sensi; Sara Lonardi; Silvia Mezi; Gianluca Tomasello; Monica Ronzoni; Alberto Zaniboni; Giuseppe Tonini; Chiara Carlomagno; Giacomo Allegrini; Silvana Chiara; Mauro D'Amico; Cristina Granetto; Marina Cazzaniga; Luca Boni; Gabriella Fontanini; Alfredo Falcone
Journal:  Lancet Oncol       Date:  2015-08-31       Impact factor: 41.316

Review 7.  Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis.

Authors:  Gaëtan Des Guetz; Olivier Schischmanoff; Patrick Nicolas; Gérard-Yves Perret; Jean-François Morere; Bernard Uzzan
Journal:  Eur J Cancer       Date:  2009-05-06       Impact factor: 9.162

8.  Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load.

Authors:  Florent Mouliere; Safia El Messaoudi; Celine Gongora; Anne-Sophie Guedj; Bruno Robert; Maguy Del Rio; Franck Molina; Pierre-Jean Lamy; Evelyne Lopez-Crapez; Muriel Mathonnet; Marc Ychou; Denis Pezet; Alain R Thierry
Journal:  Transl Oncol       Date:  2013-06-01       Impact factor: 4.243

9.  Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.

Authors:  Marc Peeters; Kelly S Oliner; Timothy J Price; Andrés Cervantes; Alberto F Sobrero; Michel Ducreux; Yevhen Hotko; Thierry André; Emily Chan; Florian Lordick; Cornelis J A Punt; Andrew H Strickland; Gregory Wilson; Tudor E Ciuleanu; Laslo Roman; Eric Van Cutsem; Pei He; Hua Yu; Reija Koukakis; Jan-Henrik Terwey; Andre S Jung; Roger Sidhu; Scott D Patterson
Journal:  Clin Cancer Res       Date:  2015-09-04       Impact factor: 12.531

10.  KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

Authors:  F Loupakis; A Ruzzo; C Cremolini; B Vincenzi; L Salvatore; D Santini; G Masi; I Stasi; E Canestrari; E Rulli; I Floriani; K Bencardino; N Galluccio; V Catalano; G Tonini; M Magnani; G Fontanini; F Basolo; A Falcone; F Graziano
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640
View more
  2 in total

1.  Dendritic cell vaccine with Ag85A enhances anti-colorectal carcinoma immunity.

Authors:  Jingbo Zhai; Wei Gao; Leheng Zhao; Zhipeng Gao; Xuefeng Jiang; Changlong Lu
Journal:  Exp Ther Med       Date:  2018-10-11       Impact factor: 2.447

2.  Novel Epigenetic Eight-Gene Signature Predictive of Poor Prognosis and MSI-Like Phenotype in Human Metastatic Colorectal Carcinomas.

Authors:  Valentina Condelli; Giovanni Calice; Alessandra Cassano; Michele Basso; Maria Grazia Rodriquenz; Angela Zupa; Francesca Maddalena; Fabiana Crispo; Michele Pietrafesa; Michele Aieta; Alessandro Sgambato; Giampaolo Tortora; Pietro Zoppoli; Matteo Landriscina
Journal:  Cancers (Basel)       Date:  2021-01-05       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.